U.S. Markets closed

Northwest Biotherapeutics' DCVax for tumors shows positive Phase I/II results

Northwest Biotherapeutics announced that, in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9 out of 9 patients who have received 4 of the 6 planned injections are showing tumor cell death, tumor shrinkage, substantial immune cell accumulation in their tumors and/or stabilization of their advanced cancer. In addition, in 3 of these 9 patients, biopsies now show no live tumor cells in the injected tumor. The company plans to report more details when the patients are further along in the treatment regimen.